Novo Dordisk Drops; Alibaba Soars; Biogen Rises
On this episode of Stock Movers:- A pill version of Novo Nordisk (NOVOB) Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk studies that aimed to open up a new use for blockbuster obesity drugs. Patients who took the medicine didn’t see their disease progress more slowly based on a cognitive assessment, the Danish drugmaker said Monday. Novo will discontinue a planned one-year extension of the studies. The stock plunged as much as 12.4% in Copenhagen, hitting the lowest level since July 2021.- Alibaba Group's (BABA) Qwen app drew more than 10…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.